Last reviewed · How we verify
NCT07459556
A Prospective Study of Stapokibart Injection in Patients With SAR
trial testing Stapokibart in SAR in 400 participants. Not yet recruiting.
1 December 2027
Quick facts
| Lead sponsor | Chengdu Kangnuoxing Biopharma,Inc. |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 March 2026 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 February 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Stapokibart — full drug profile →
Conditions studied
- SAR — all drugs for SAR →
Sponsor
Chengdu Kangnuoxing Biopharma,Inc. — full company profile →
Who can join
18 and older, any sex, with SAR. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The incidence rate of adverse reactions (ADR).
Time frame: From enrollment to the end of treatment at 10 weeks
Number of of Adverse Reactions （ADRs） is calculated based on Adverse Events （AEs） and Serious Adverse Events （SAEs） that were assessed by the investigator as related to the study drug and categorized according to the Medical Dictionary for Regulatory Activities （MedDRA）.
Sponsor's own description
This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07459556
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stapokibart
Trials testing the same drug.
- NCT07143864 — Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis · NA · not yet recruiting
- NCT06801353 — A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps · Phase 4 · not yet recruiting
- NCT06424470 — Study on the Treatment of Prurigo Nodularis With Stapokibart Injection · Phase 3 · active not recruiting
Other Chengdu Kangnuoxing Biopharma,Inc. trials
Trials by the same sponsor.
- NCT07210554 — Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07459556 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chengdu Kangnuoxing Biopharma,Inc.
- Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07459556.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing